RANKL Polyclonal antibody

RANKL Polyclonal Antibody for IHC, ELISA

Host / Isotype

Rabbit / IgG


human and More (2)


WB, IF, IHC, ELISA, Cell treatment



Cat no : 23408-1-AP


CD254, hRANKL2, ODF, OPGL, OPTB2, Osteoprotegerin ligand, RANKL, sOdf, TNFSF11, TRANCE

Tested Applications

Positive IHC detected inhuman stomach cancer tissue, human colon tissue, human heart tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

Immunohistochemistry (IHC)IHC : 1:50-1:500
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

23408-1-AP targets RANKL in WB, IF, IHC, ELISA, Cell treatment applications and shows reactivity with human samples.

Tested Reactivity human
Cited Reactivityhuman, mouse, rat
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen RANKL fusion protein Ag19975
Full Name tumor necrosis factor (ligand) superfamily, member 11
Calculated Molecular Weight 317 aa, 35 kDa
GenBank Accession NumberBC074890
Gene Symbol TNFSF11
Gene ID (NCBI) 8600
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

TNFSF11 also known as RANKL, is a member of the tumor necrosis factor (TNF) cytokine family which is a ligand for osteoprotegerin and functions as a key factor for osteoclast differentiation and activation. RANKL is a polypeptide of 217 amino acids that exerts its biological activity both in a transmembrane form of about 40-45 kDa and in soluble one of 31 kDa (PMID: 15308315). The membrane-bound RANKL (mRANKL) is cleaved into a sRANKL by the metalloprotease-disintegrin TNF-alpha convertase (TACE) or a related metalloprotease (MP). RANKL induces osteoclast formation through its receptor, RANK, which transduces signals by recruiting adaptor molecules, such as the TNF receptor-associated factor (TRAF) family of proteins. RANKL was shown to be a dentritic cell survival factor and is involved in the regulation of T cell-dependent immune response. T cell activation was reported to induce expression of this gene and lead to an increase of osteoclastogenesis and bone loss. RANKL was shown to activate antiapoptotic kinase AKT/PKB through a signaling complex involving SRC kinase and tumor necrosis factor receptor-associated factor (TRAF) 6, which indicated this protein may have a role in the regulation of cell apoptosis.


Product Specific Protocols
IHC protocol for RANKL antibody 23408-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols



J Extracell Vesicles

Exosomes derived from osteogenic tumor activate osteoclast differentiation and concurrently inhibit osteogenesis by transferring COL1A1-targeting miRNA-92a-1-5p.

Authors - Lijuan Yu

Aging Cell

Pyrroloquinoline quinone alleviates natural aging-related osteoporosis via a novel MCM3-Keap1-Nrf2 axis-mediated stress response and Fbn1 upregulation

Authors - Jie Li

J Control Release

Sialic acid-modified chitosan oligosaccharide-based biphasic calcium phosphate promote synergetic bone formation in rheumatoid arthritis therapy.

Authors - Xiao-Ling Xu

Mol Metab

Loss of chemerin triggers bone remodeling in vivo and in vitro.

Authors - Long Han

Aging (Albany NY)

Increased expression of osteopontin in subchondral bone promotes bone turnover and remodeling, and accelerates the progression of OA in a mouse model.

Authors - Chuangxin Lin
mouseCell treatment

Int Immunopharmacol

Clearance of senescent cells by navitoclax (ABT263) rejuvenates UHMWPE-induced osteolysis

Authors - Weiping Su